Lipocine Inc. — FY2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019. The filing was signed in March 2020 and includes material subsequent events through that date. Lipocine is a clinical-stage biopharmaceutical company developing oral drug-delivery products; it had no approved products or product sales revenue.
Financial results and liquidity
| Metric | FY2019 / Dec. 31, 2019 | FY2018 / Dec. 31, 2018 |
|---|---|---|
| Revenue | $165,000, from licensing royalties | $428,000 |
| Research and development expense | $7.47 million | $6.46 million |
| General and administrative expense | $5.60 million | $5.29 million |
| Operating loss | $12.90 million | $11.33 million |
| Net loss | $13.01 million; $0.50 per share | $11.66 million; $0.55 per share |
| Cash used in operating activities | $11.67 million | $12.08 million |
| Cash, cash equivalents and marketable securities | $14.07 million unrestricted; $5.00 million additional restricted cash | $15.25 million unrestricted; $5.00 million restricted |
| Total liabilities / debt | $13.37 million total liabilities; about $7.15 million debt carrying value | $11.42 million total liabilities; about $10.26 million debt carrying value |
| Total assets / shareholders’ equity | $19.66 million / $6.29 million | $20.85 million / $9.43 million |
No meaningful operating margin is indicated given the very small royalty revenue and absence of product sales. The company reported an accumulated deficit of $151.1 million. The $5.0 million restricted cash balance is collateral under the SVB loan and remains restricted until TLANDO is FDA-approved.
Changes versus FY2018
- Revenue declined about 61%, reflecting lower Spriaso royalty payments.
- Operating loss increased about 14%; R&D expense rose about 16%, primarily as LPCN 1144’s LiFT Phase 2 study began. G&A expense rose about 6%, mainly due to Clarus patent-litigation costs, partly offset by lower personnel costs.
- Operating cash use improved modestly, while cash and marketable securities declined by about $1.18 million on an unrestricted basis.
- Financing included approximately $6.0 million gross proceeds from the November 2019 offering and $8.0 million net proceeds from ATM stock sales; $3.33 million of loan principal was repaid. The November offering also created a $4.59 million warrant liability at year-end and a $236,000 noncash fair-value gain.
Business, outlook and key risks
- TLANDO: FDA issued a Complete Response Letter on November 8, 2019, citing failure to meet three secondary maximum-testosterone-concentration endpoints; it identified no specific CMC issue. Following FDA feedback, Lipocine resubmitted its NDA on February 28, 2020, with an August 28, 2020 PDUFA date. This was the third CRL for TLANDO. The company’s pathway depends on FDA review of a reanalysis of existing data; approval and timing remain uncertain.
- Safety and competition: In the open-label ABPM study, mean 24-hour systolic blood pressure increased 3.82 mm Hg and diastolic pressure increased 1.20 mm Hg. Lipocine warns of possible cardiovascular-related regulatory requirements. Oral competitor JATENZO was approved in 2019 and launched in February 2020; its exclusivity and a Citizens Petition may affect TLANDO’s timing or approval.
- LPCN 1144: The company reported positive liver-fat findings from a 16-week proof-of-concept study, including NAFLD resolution in 48% of treated subjects meeting the study’s baseline-fat definition. The placebo-controlled LiFT Phase 2 study was underway. Management expected MRI-PDFF top-line data in the second half of 2020 and biopsy data in the first half of 2021; these were forward-looking expectations, not reported results.
- Other programs: Management planned to prioritize TLANDO and LPCN 1144 in 2020. It did not expect to start Phase 3 TLANDO XR or LPCN 1107 studies, or a Phase 2 LPCN 1148 study, in 2020 absent additional capital or licensing. No such licensing agreements had been signed.
- Funding and debt: Management estimated existing resources would fund operations through at least March 31, 2021, subject to assumptions, but said additional capital would ultimately be needed. A February 2020 offering raised about $6.0 million gross (approximately $5.63 million after stated fees and expenses). The SVB loan bears interest at prime plus 1% (6% at year-end), matures December 2021, carries a $650,000 final payment charge and restrictive covenants, and is secured by substantially all assets except intellectual property. Failure to raise capital could force program reductions or threaten continued operations.
- Litigation and other contingencies: Pending matters include a shareholder derivative suit and a securities class action related to TLANDO disclosures, as well as patent litigation involving Clarus/JATENZO and an appeal concerning Clarus’s patent. Outcomes and potential losses are uncertain; the company recorded no liability for the shareholder suits. A prior securities class action was settled for $4.3 million in 2018, largely covered by insurance.
- Additional risks: The company depends on third-party manufacturers and a single TU supplier; has no established commercial sales force; faces clinical, regulatory, reimbursement, patent, and product-liability risks; and identified the emerging coronavirus outbreak as a potential source of business disruption. Nasdaq had notified the company of a minimum-bid-price deficiency, with an initial compliance deadline of June 24, 2020.
The independent auditor issued an unqualified opinion on the consolidated financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor was not engaged to opine on internal-control effectiveness.
Most important facts for investors to verify
- FDA’s decision and any additional requirements for TLANDO, including the impact of the Cmax reanalysis, blood-pressure findings, JATENZO exclusivity and the Citizens Petition.
- Actual LPCN 1144 LiFT enrollment, data timing, results and cash required to complete development.
- Current unrestricted liquidity, cash burn, funding runway, subsequent financing proceeds and likely dilution from outstanding warrants and future capital raises.
- SVB loan compliance, repayment schedule, cash-collateral restrictions and the effect of its covenants and final payment charge.
- Status, potential costs and insurance coverage of shareholder and patent litigation, including the Clarus appeal and JATENZO patent case.
- Progress on manufacturing supply continuity, commercial readiness and Nasdaq listing compliance.